Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Zirdu who wrote (964)	4/12/1999 12:50:00 PM
From: Mike McFarland	Respond to of 3202

A walk-through on how to begin your due diligence... If you have not yet seen it, look down an inch below the bottom of this text box and you will see a row of links, one of which is PROFILE, in the middle. The profile for Incyte here on SI is very good--much more detailed than the one you would find at the Yahoo quote website. One or two of these genomics related companies are written up in Value Line--HGSI for example, but you wont find MLNM or INCY there, not yet anyway--they should be there. I could not find a profile for MLNM here on SI...but here is the url to the Yahoo profile-- it is not especially detailed, you'll probably have to read through some of the MLNM thread to get a better feel. biz.yahoo.com I think the short answer is that Incyte is more of a pure play on the bioinformatics business model, while companies like HGSI, and especially MLNM want also to be developers of drugs based on the genome data. For instance, MLNM has a couple of lead compounds which come up if you do a query on the recap website, and HGSI turns up three phase II clinical trials, and several leads as well. I just took you to second grade as far as DD... a read of the recent hundred or so posts to the SI thread on INCY will get you to third grade...calling or writing investor relations to get a packet, and reading through all the press releases gets you to fourth. If you went through the posts to and from Rocketman, working backward a few hundred posts, that will get you to fifth grade. After about a year of following these biotech stocks I get the impression that the mutual fund managers have been left behind from the fifth grade--but maybe that is because they communicate so poorly in their annual reports to mutual fund holders--which is the reason I mostly have individual biotech stocks now. (I don't own Incyte yet...but at $19/share the other day I was as close to buying as I have been since I started lurking here, too bad I didn't grab some...a nice move today). If a person gets a book published on investing...that is middle school; investors that do well and beat the index over a decade go to high school. Warren Buffet is in college. Enlightened individuals who start their own company and write themselves options were clever enough to drop out. Hope that was helpful (I am so full of crap sometimes) --the biotech followers here on SI are most kind and helpful...I am sure if you have further questions they will help you out if you have further questions and post again sometime. Happy hunting, Mike

To: Zirdu who wrote (964)	4/12/1999 5:00:00 PM
From: Steven Rachbach	Read Replies (1) \| Respond to of 3202

I have been trying in vain to ascertain why the likes of INCY, AFFX and HGSI would be up sharply today all on 5 to 6 times the normal trading volume. It would seem at first glance that today's news story about the major pharm cos. banding together to map genes to "try to find new drugs without paying millions of dollars to small biotechnology companies" would have a negative impact on our the "small biotechnology companies'" stock price. Any thoughts? Perhaps the realization that the majors are doing this indicates the value of our company?